E-Sync T Cell Therapy (University of California/National Cancer Institute/California Institute for Regenerative Medicine)

N/A

Report date: 2025/06/11 20:01:15

Base Information

Drug NameE-Sync T Cell Therapy (University of California/National Cancer Institute/California Institute for Regenerative Medicine)
Drug Alias Nameautologous anti-EGFRvIII synNotch receptor induced anti-EphA2/IL-13R alpha2 CAR T cell therapy (University of California/National Cancer Institute/California Institute for Regenerative Medicine)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionEphrin type-A receptor 2 modulatorsImmunostimulantsEpidermal growth factor receptor erbB1 modulators +[5] 
TargetsInterleukin-13 receptor subunit alpha-2Epidermal growth factor receptor erbB1Ephrin type-A receptor 2
Therapy Area/IndicationsGlioblastoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of California San Francisco
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of California San FranciscoCalifornia Institute Regenerative MedNational Cancer Institute
Inactive CompaniesN/A
Active IndicationsGlioblastoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A